Amylyx Pharmaceuticals (AMLX) Stock Forecast & Price Target

Amylyx Pharmaceuticals is viewed favorably because its lead asset avexitide produced a highly statistically significant 55% reduction versus placebo in the Phase 3 LUCIDITY trial, met all secondary endpoints, and showed a clean safety profile with no serious treatment-related adverse events. The company also benefits from a large, underpenetrated post-bariatric hypoglycemia opportunity, with estimates of about 30,000 severe and 160,000 moderate-to-severe U.S. patients, Breakthrough Therapy and Orphan Drug Designations, and a path to an NDA by year-end that supports a potentially timely review. Fundamentally, the positive outlook is reinforced by strong physician interest, an opened U.S. Expanded Access Program, and a pipeline beyond avexitide that includes AMX0318, which could extend the franchise and improve long-term revenue durability.

Amylyx Pharmaceuticals is a clinical-stage company with no approved diversified commercial base, leaving it heavily dependent on pipeline execution and the eventual success of avexitide, AMX0035, AMX0114, and AMX0318 across highly uncertain rare-disease indications. The investment case is especially fragile because the company faces meaningful downside risk if Phase 3 data in adults with PBH falls short on efficacy or safety, or if R&D, regulatory, or commercial development is delayed. Competitive pressure in PBH and the possibility that the PBH market opportunity is smaller than expected further weaken the fundamental outlook and increase the risk that future value creation disappoints.